Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine Hydrochloride and Tropicamide, the active ingredients in Mydriasert, are mydriatic agents presented as an ocular solution for ocular use. The formulation is indicated for diagnostic and surgical procedures where controlled mydriasis is essential, and it is approved for use in the European Union. They produce rapid pupil dilation and temporary paralysis of the ciliary muscle, facilitating detailed retinal examination and intra‑ocular surgical access in adult patients.

GNH USA supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics, and research institutions worldwide, ensuring reliable quality and regulatory compliance for global ophthalmic care.

Mydriasert, a combination mydriatic ophthalmic solution, is used in ophthalmology to achieve pupil dilation.

Diagnostic eye examinations: provides rapid pupil dilation for thorough retinal evaluation. Intra‑ocular surgery: facilitates adequate pupil size for surgical access. Cycloplegic testing: temporarily paralyzes accommodation for accurate refraction assessment.

Mydriasert may cause ocular and systemic reactions after administration.

Common Side Effects: - Transient eye burning or stinging sensation. - Redness of the conjunctiva. - Temporary blurred vision. - Mild increase in intra‑ocular pressure. - Light sensitivity. - Mild headache.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma. - Severe ocular pain or prolonged dilation. - Systemic hypertension or tachycardia. - Allergic reactions including rash or swelling. - Anaphylaxis. - Persistent cycloplegia beyond expected duration.

Before using Mydriasert, consider the following precautions.

Assess intra‑ocular pressure: avoid in patients with narrow‑angle glaucoma. Monitor cardiovascular status: phenylephrine may raise blood pressure. Avoid in children unless directed: safety data are limited. Check for hypersensitivity: discontinue if allergic reaction occurs. Store at room temperature: keep in the original container, protect from light and moisture.

Mydriasert can interact with other medications; review patient medication lists.

Major Interactions (Avoid): - Systemic sympathomimetics: additive hypertensive effect. - Monoamine oxidase inhibitors: risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Topical beta‑blockers: may mask phenylephrine‑induced tachycardia. - Anticholinergic drugs: enhanced cycloplegic effect. - Other mydriatics: increased risk of prolonged dilation.